News

Administering the maresin-1 molecule — a natural anti-inflammatory in the body — in a mouse model of multiple sclerosis (MS) led to lower levels of inflammation and improved neurological function, a recent study showed. Maresin-1 and other molecules in its family are called specialized pro-resolving mediators (SPMs) and are…

More than half of Canadians with multiple sclerosis (MS) report using cannabis to help manage their symptoms, according to a new study. The study, “Medical cannabis use in Canadians with multiple sclerosis,” was published in Multiple Sclerosis and Related Disorders. Humans have used the cannabis plant for millennia,…

Tysabri (natalizumab) given every six weeks was found to be similarly effective as the standard four-week dosing schedule at stopping nervous system damage in people with relapsing-remitting multiple sclerosis (RRMS). That’s according to the full results of the Phase 3b NOVA clinical trial, which compared Tysabri dosing schedules…

The uncertainties that accompany multiple sclerosis (MS) are among the biggest challenges faced by people with the disease, with two-thirds of patients in a recent survey saying “they’re scared for the future” because of such unknowns, the MS Society, which conducted the U.K. survey, reports. “We may all think the…

In an unusual challenge, the Multiple Sclerosis Society of Canada is raising millions to promote multiple sclerosis (MS) research in that country by having supporters rappel off the roof of a downtown Toronto office building. More than 145 individuals across at least 36 teams are expected to participate in the…

The National Institute for Health and Care Evidence (NICE) in England has issued a briefing on the use of Icometrix‘s icobrain system to assess disease activity in people with multiple sclerosis (MS) based on MRI scans. The NICE statement was in the form of a medtech innovation briefing, or…

The portable neuromodulation stimulator (PoNS) device, which improves walking abilities in people with multiple sclerosis (MS), is now available commercially in the U.S. for patients ages 22 and older who have a prescription from their healthcare provider. The device was approved last year by the U.S. Food…

Multiple sclerosis (MS) affects all aspects of life, from physical and mental health to relationships, and from work and finances to hobbies and holidays, according to results from an online survey conducted by the U.K.’s MS Trust. Most respondents said they wanted more support to manage their fatigue, improve…

Quanterix’s ultra-sensitive blood test that measures a biomarker of nerve damage in people with multiple sclerosis (MS) has been granted a breakthrough device designation by U.S. regulators. It is thought that the test, which employs the company’s Simoa technology, can accurately predict the risk of disease activity in…

Long-term treatment with tolebrutinib significantly reduced signs of disease-related brain damage in people with relapsing multiple sclerosis (MS), according to new data from a Phase 2 clinical trial and its extension study. Specifically, the investigational oral therapy was found to keep the number of inflamed brain lesions…

Kesimpta (ofatumumab) is now accessible to eligible Canadians with relapsing-remitting multiple sclerosis (RRMS) through public drug plans in Ontario and Quebec. The treatment has been included as an exceptional medication under both the Ontario Drug Benefit Exceptional Access Program and the Régie de l’assurance maladie du Québec. This…

Children with multiple sclerosis (MS) who in their first year after disease onset experience pyramidal symptoms, such as spasticity or weakness, visual problems, or show signs of cerebellum involvement like poorer coordination are more likely to have worse long-term disability, an analysis of registry data indicates. The analysis also…

The first participant has been enrolled in a new clinical trial that is testing whether an antihistamine in combination with a diabetes medication might promote the repair of the myelin sheath in people with multiple sclerosis (MS). The trial’s first participant, Annabelle, was diagnosed with relapsing MS over a…

More relapsing multiple sclerosis (MS) patients given ublituximab remained relapse-free over the two-year long Phase 3 ULTIMATE clinical trials, compared to those given Aubagio (teriflunomide), new data show. “The prevention of relapses represents an important goal of disease-modifying therapy with the potential for a marked impact on the accumulation of disability,” Lawrence Steinman,…

Serum levels of neurofilament light chain (NfL) — proteins found in nerve cell projections — can help in the prediction of disease progression among people with relapsing forms of multiple sclerosis (MS), according to an analysis of data from two large Phase 3 trials. The researchers said that NfL…

Plegridy (peginterferon beta-1a), an approved treatment for relapsing multiple sclerosis (MS), is detected at minimal concentrations in the breast milk of patients using the therapy postpartum, a small study showed. This is in line with label updates on Plegridy and other interferon beta therapies in Europe and…

The Multiple Sclerosis Association of America (MSAA) is presenting virtual and in-person ways to support its eighth annual Improving Lives Benefit, which will showcase more than a half-century of efforts for the multiple sclerosis (MS) community. The virtual event, themed “Together at Home,” will be held at…

The National Medical Products Administration (NMPA) of China has agreed to approve a Phase 2 trial testing the safety and efficacy of the investigational therapy SN1011 in people with multiple sclerosis (MS). SN1011 is being developed by SinoMab Bioscience to treat a range of autoimmune and inflammatory…

There is minimal data available on the safety of most disease-modifying therapies for multiple sclerosis (MS) when used during breastfeeding, a new review indicates. The study “Disease-Modifying Drugs and Breastfeeding in Multiple Sclerosis: A Narrative Literature Review,” was published in Frontiers in Neurology. Disease-modifying therapies, or DMTs,…

A program aimed at optimizing the use of highly effective therapies successfully lowered treatment costs and relapse rates among people with multiple sclerosis (MS) in Southern California, according to a study. “Our novel physician-led approach simultaneously reduced MS DMT [disease-modifying therapy] expenditures and the frequency of MS relapses. We…

Loss of gray matter in the spinal cord clearly associates with greater disability in people with multiple sclerosis (MS), but determining the extent of its loss is limited by an inability to accurately measure gray matter in all patients, a small study in Spain reported. The true amount of…

Physician-researchers at Cedars-Sinai Medical Center, in California, are developing brain and eye imaging techniques to improve the diagnosis and management of multiple sclerosis (MS). MS is characterized by the progressive loss of myelin, the fatty protective sheath around nerve fibers, in the brain and spinal cord due to abnormal…

Treatment with Gilenya (fingolimod) for up to four years was found safe and lowered relapse rates among people with multiple sclerosis (MS) in the Czech Republic, according to a real-world study called GOLEMS. Older age, lower disability level, and fewer relapses prior to the treatment’s start were all…

Atara Biotherapeutics plans to launch two Phase 3 clinical trials of its investigational immunotherapy ATA188 in people with non-active, progressive forms of multiple sclerosis (MS). Whether efforts for these trials will go forward, however, depends on positive results from an interim analysis of the Phase 2 portion of the…

Greater engagement in social activities and positive social support were associated with better physical and psychological health among people with multiple sclerosis (MS) in a recent study. These data “suggest that social integration and social support should be a crucial part of MS management,” the researchers wrote, adding that…

Repeat harvesting of bone marrow cells and infusing them back into the bloodstream is safe and feasible in people with active progressive multiple sclerosis (MS), according to data from a small, proof-of-concept clinical trial. Results were detailed in the study, “Repeat infusion of autologous bone marrow…

People newly diagnosed with multiple sclerosis (MS) in Norway have in recent years received disease-modifying therapies (DMTs) independent of their socioeconomic status, according to a new analysis. These findings do not support previous reports indicating that fewer DMTs are prescribed for the most socially deprived MS patients, the…

A Phase 1/2 clinical trial evaluating Imcyse’s experimental therapy IMCY-0141 in people with relapsing-remitting multiple sclerosis (RRMS) has dosed its first patient. The trial, called IMCY-MS-001, is expected to enroll nearly 150 adults with RRMS; sites were not disclosed in a release by the Belgium-based company. Interim results may be available…

The National Institute for Health and Care Excellence (NICE) has added oral Vumerity (diroximel fumarate), approved to treat relapsing-remitting multiple sclerosis (RRMS) in the U.K., to the list of medications available through the public health program for England. Because the therapy has been recommended through a fast track appraisal process, Vumerity…

An intervention that involves training to recognize facial expressions, and also mimicking these expressions, may help people with multiple sclerosis (MS) who have trouble recognizing facial affect, according to data from a small clinical trial. These findings were reported in the study “Emotional processing intervention (EMOPRINT):…